Research programme: gene editing based therapeutics - Bayer - CRISPR Therapeutics (JV)

Drug Profile

Research programme: gene editing based therapeutics - Bayer - CRISPR Therapeutics (JV)

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Casebia Therapeutics; CRISPR Therapeutics
  • Developer Casebia Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blindness; Congenital heart defects; Haematological disorders; Immunodeficiency disorders

Most Recent Events

  • 14 Mar 2017 Crispr and Casebia in-licenses Flow Electroporation™ technology from MaxCyte
  • 10 Mar 2017 Preclinical trials in Haematological disorders, Congenital heart disorders and Blindness in United Kingdom (unspecified route)
  • 10 Mar 2017 Preclinical trials in Immunodeficiency disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top